Comparison of dual-immunosuppressive therapy and a voclosporin-based, triple-immunosuppressive regimen for lupus nephritis: A propensity analysis of ALMS and AURORA 1 (UKKW 2024) - Jun 8, 2024 - Abstract #377; 191; Location: HARRIS; "Background To understand the safety and efficacy of a voclosporin-based, mycophenolate mofetil (MMF) and glucocorticoid-sparing, triple immunosuppressive regimen as an initial approach to therapy in active lupus nephritis compared to conventional high-dose MMF and glucocorticoid regimens, we compared and analyzed clinical data in propensity-matched patients from ALMS and AURORA 1. In the first 3 months, significantly more patients in AURORA 1 achieved >25% UPCR reduction from baseline (81.3% AURORA 1, 65.6% ALMS; p=0.011); the proportions of patients achieving UPCR ≤0.5 mg/mg and >50% UPCR reduction from baseline were numerically greater in the voclosporin arm; the differences were not statistically significant. Conclusion The above findings affirm the KDIGO 2023 recommendation that a voclosporin-based, triple immunotherapy regimen should be considered as initial therapy in active lupus nephritis."
CNS Disorders • Gastrointestinal Disorder • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Mental Retardation • Nephrology • Psychiatry
|
|
Dr Ernie Yap1; Dr Maria Dall'Era2; Dr Matt Truman1; Dr Lucy Hodge1; Dr Neil Solomons3; Melanie Edwards4
|